Little Warrior Foundation Inc is located in Brookfield, WI. The organization was established in 2020. According to its NTEE Classification (T12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. As of 09/2023, Little Warrior Foundation Inc employed 3 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Little Warrior Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 09/2023, Little Warrior Foundation Inc generated $1.7m in total revenue. This organization has experienced exceptional growth, as over the past 3 years, it has increased revenue by an average of 36.8% each year . All expenses for the organization totaled $532.6k during the year ending 09/2023. While expenses have increased by 4.6% per year over the past 3 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO FUND AND FIND A LASTING CURE FOR CHILDHOOD CANCER, WITH A SPECIFIC FOCUS ON EWING SARCOMA.
Describe the Organization's Program Activity:
Part 3 - Line 4a
FUNDING GRANTS FOR RESEARCH FOR EWING'S SARCOMA.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Piero Spada Co-Founder / President | OfficerTrustee | 10 | $0 |
Maggie Spada Co-Founder / Board Member | Trustee | 10 | $0 |
Emily Mcfadden Co-Founder / Board Member | Trustee | 10 | $54,300 |
Mike Burton Board Member | Trustee | 1 | $0 |
Tim Frank Board Member | Trustee | 1 | $0 |
Melissa Oberst Board Member | Trustee | 1 | $0 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $862,828 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $887,510 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,750,338 |
Total Program Service Revenue | $0 |
Investment income | $45,264 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | -$98,399 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $12,339 |
Miscellaneous Revenue | $0 |
Total Revenue | $1,709,542 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $275,000 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $62,147 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $0 |
Payroll taxes | $4,754 |
Fees for services: Management | $0 |
Fees for services: Legal | $0 |
Fees for services: Accounting | $16,790 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $102,418 |
Advertising and promotion | $39,818 |
Office expenses | $22,404 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $0 |
Travel | $1,291 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $5,037 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $0 |
Insurance | $1,494 |
All other expenses | $1,418 |
Total functional expenses | $532,571 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $330,685 |
Savings and temporary cash investments | $1,983,201 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $103,150 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $37,474 |
Prepaid expenses and deferred charges | $0 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $2,454,510 |
Accounts payable and accrued expenses | $39,563 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $39,563 |
Net assets without donor restrictions | $2,414,947 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $2,454,510 |
Over the last fiscal year, Little Warrior Foundation Inc has awarded $427,500 in support to 4 organizations.
Grant Recipient | Amount |
---|---|
CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTE PURPOSE: THIRD INSTALLMENT TO SISU PROJECT, PRE-CLINICAL RESEARCH FOR A VIABLE MAINTENANCE THERAPY FOR EWS | $37,500 |
BEAT CHILDHOOD CANCER PURPOSE: IN:FORMATION EWING SARCOMA PRECISION MEDICINE PROGRAM SPEARHEADED BY DR. SHOLLER | $65,000 |
THE CLEVELAND CLINIC FOUNDATION PURPOSE: PRE-CLINICAL VALIDATION STUDIES FOR PERSONALIZED MRNA VACCINE - DR. TIMOTHY CHAN AND COMPENSATION IN SUPPORT OF PRINCIPAL INVESTIGATOR IN EWS CLINICAL TRIAL | $275,000 |
MEMORIAL SLOAN KETTERING CANCER CENTER PURPOSE: PHASE II STUDY OF THE ORAL CHK1 INHIBITOR / LOW-DOSE GEMCITABINE IN EWS PATIENTS | $50,000 |